NCT02100631CompletedPhase 3
A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 O1 Serotype Inaba Strain CVD 103-HgR
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Bavarian Nordic
- Enrollment
- 398
- Locations
- 32
- Primary Endpoint
- Seroconversion Rate at Day 11
Study Overview
Brief Summary
Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
Detailed Description
Demonstrate that seroconversion by classical Inaba vibriocidal antibody at Day 11 in older adults ages 46-64 years (inclusive) was non inferior to seroconversion at Day 11 in younger adults ages 18-45 years following vaccination with PXVX0200.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 46 Years to 64 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Able to understand the study and give written consent.
- •Healthy male and female adults, age 46-64 years (inclusive) without significant medical history, physical, or abnormal screening laboratory test results at screening.
- •Women of childbearing potential must have had a negative urine pregnancy test at screening, prior to vaccination. Female subjects must be of non-childbearing potential (as defined as surgically sterile or postmenopausal for more than 1 year), or if of childbearing potential must be practicing abstinence or using an effective licensed method of birth control (eg, use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, intrauterine devices [IUDs], cervical sponges, diaphragms, condoms with spermicidal agents; or must have a vasectomized partner) within 2 months of vaccination and must agree to continue such precautions during the study.
- •Willing and able to comply with the study requirements and procedures.
Exclusion Criteria
- •Currently active unstable or undiagnosed medical conditions including immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse. Examples of unstable or undiagnosed medical conditions including unstable angina pectoris, shortness of breath on exertion without clear etiology and chronic renal failure requiring dialysis. Examples of conditions that do not meet exclusion criteria include mild controlled hypertension, mild controlled asthma, and treated depression without hospitalization.
- •Abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months.
- •Regular use of laxatives in the past 6 months.
- •Previously received a licensed or investigational cholera vaccine.
- •History of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge).
- •Travel to a cholera-endemic area in the previous 5 years.
- •Received or plans to receive any other licensed vaccines, except for seasonal influenza vaccine, from 14 days prior to the study vaccination through to 29 days after vaccination.
- •Received or plans to receive antibiotics or chloroquine within 14 days prior to the study vaccination through to 29 days after vaccination.
- •Recipient of bone marrow or solid organ transplant.
- •Use of systemic chemotherapy in the previous 5 years prior to the study.
- •Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years.
- •Received or plans to receive systemic immunosuppressive therapy, radiation therapy, parenteral or high-dosage inhaled steroids (>800 µg/day of beclomethasone diproprionate or equivalent) within 6 months prior to the study vaccination through to Day
- •History of Guillain-Barré Syndrome.
- •Pregnant or nursing.
Outcomes
Primary Outcomes
Seroconversion Rate at Day 11
Time Frame: Day 11
The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.
Secondary Outcomes
- Geometric Mean Titer (GMT)(Day 11)
Investigators
Study Sites (32)
Loading locations...
Similar Trials
Completed
Phase 3
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the ElderlyOrthomyxoviridae InfectionMyxovirus InfectionInfluenzaNCT00391053Sanofi Pasteur, a Sanofi Company3,851
Not yet recruiting
Phase 3
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)RabiesNCT05969626Ningbo Rongan Biological Pharmaceutical Co., Ltd.2,460
Completed
Phase 3
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsSmallpoxNCT01144637Bavarian Nordic4,005
Completed
Phase 3
Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)InfluenzaNCT00240877MedImmune LLC330
Completed
Phase 3
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420